Cocoa/commodity inflation crushing gross margin faster than pricing can recover it
One-line thesis. Mondelez is a genuinely durable global snacking franchise (Oreo, Cadbury, Milka, belVita) throwing off ~$3.2B of free cash flow — but a historic cocoa-cost shock collapsed 2025 GAAP earnings (EPS $1.89 vs $3.44), the stock still trades ~20× forward for only ~3% revenue / ~8% EPS growth, and there is no expert conviction in our KB, so it earns a Watch, not a buy.
◆ Synthos call — HoldMDLZ is a solid business largely reflected at ~$64 — fine to keep, no reason to chase; it gets interesting again below ~$54.
Downside Risk (lower = safer)
5/10 · Moderate
Low beta (0.40) & defensive demand — offset by 3.9× net-debt/EBITDA, 96% payout, and a cocoa-cost margin shock.
Growth Quality
4/10 · Moderate
Only ~3% forward revenue and ~8% EPS CAGR; 2025 gross margin collapsed to 29% on cocoa; ROIC ~6%.
Exponential Potential
2/10 · Low
Mature snacking staple; low-single-digit growth, no acceleration, $78B cap vs a saturated TAM — no multibagger here.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 8%/yrTo justify today’s $61, earnings would have to compound roughly 8% a year for 10 years (9% discount rate). Analysts forecast ~6%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Mondelez is the company behind Oreo cookies, Cadbury and Milka chocolate, Ritz crackers, belVita, and Trident gum — snacks sold in almost every country on earth. It's a slow, steady "eat-in-any-economy" business, and it pays a solid dividend (about 3.3% a year).
The problem right now: the price of cocoa (the main ingredient in chocolate) spiked to record highs, and that ate into the company's profits — reported earnings roughly halved in 2025. The company is raising prices to catch up, but that takes time and can push shoppers toward cheaper store brands.
Is the stock cheap or expensive? It's fairly priced, leaning slightly expensive — you're paying about 20 times next year's expected earnings for a company growing only a few percent a year. Our verdict is Watch: a fine, safe business, but there's no bargain and no fast growth here today.
Here's what our three scores mean in everyday terms:
Downside Risk 5/10 (middle). The stock is calm and defensive (people keep buying snacks in a recession), but the company carries a fair bit of debt and pays out almost all of its earnings as dividends, so there's little cushion if profits stay squeezed.
Growth Quality 4/10 (below average). It grows slowly, and the recent cocoa shock hurt profitability.
Exponential Potential 2/10 (low). This is a mature giant. Don't expect the stock to double quickly — it's a tortoise, not a rocket.
The one big worry: if cocoa and other ingredient costs stay high, margins may not recover as fast as hoped, and price hikes could drive shoppers to cheaper brands.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLP (sector)), set to 100 a year ago
Solid = MDLZ · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$60.91
Market cap$78B
P/E trailing3×
P/E FY26E / FY27E20× / 18×
EV / Sales2.5×
EV / EBITDA19.2×
Gross margin28.8%
Net margin6.6%
Dividend yield3.28%
Beta0.4
52-wk range$52 – $71
RSI(14)41
50 / 200-DMA$61 / $59
12-mo return+-12% (SPY +21%)
Street target$67 ($61–$73)
Analyst grades31 Buy · 8 Hold · 2 Sell
FMP ratingB
Next earnings2026-08-05
What the experts actually said 0 traceable claims on MDLZ · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Mondelez International (NASDAQ: MDLZ) is a global snacking company spun out of Kraft Foods in 2012, headquartered in Chicago and led by CEO Dirk Van de Put. Its portfolio is anchored by two power categories — biscuits/crackers (Oreo, belVita, Ritz, LU, TUC) and chocolate (Cadbury, Milka, Toblerone) — plus gum & candy (Trident, Halls, Sour Patch Kids), cheese & grocery, and powdered beverages (Tang). Fiscal year ends December 31. Beta is a low 0.40 and the dividend yield is ~3.3% — classic consumer-defensive ballast.
Revenue mix (FY2025, from filings):
By product: Biscuits & Baked Snacks $18.39B (48%) · Chocolate $12.70B (33%) · Gum & Candy $4.06B (11%) · Cheese & Grocery $2.38B (6%) · Beverages $1.01B (3%). The business is a biscuits-plus-chocolate story; chocolate is where the cocoa-cost pain concentrates.
By geography: Europe $15.03B (39%) · North America $10.68B (28%) · Asia/Middle East/Africa $7.93B (21%) · Latin America $4.90B (13%). Unlike most US megacaps, Mondelez is majority ex-US — a diversification strength but an FX and emerging-market headwind.
The strategic frame is simple: defend and grow the two core categories, take pricing to offset input inflation, and lean on emerging-market volume. There is no transformational growth engine — this is a share-taking-and-pricing staple.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of Mondelez in the Synthos knowledge base.total_claims = 0, net_bullish_voices = 0, and the top array is empty in MDLZ.json. No independent analyst, podcaster, or investor voice we track has made a reconcilable, dated claim on this name.
What that means for this note: the verdict here is fundamentals- and quant-driven only. We are not borrowing anyone else's conviction, and — per house standard — we will not manufacture it. Every judgment below is built from the reported financials, the FMP analyst-estimate consensus (labeled as estimates), and the technical block. Where the Street has a view, we show it as context (31 Buy / 8 Hold / 2 Sell, $67 median target), not as our anchor.
The absence of KB coverage is itself a (soft) signal: this is a well-understood, slow-growth staple that the forward-looking, exponential-hunting voices Synthos tracks simply do not spend time on. That is consistent with our Watch, not a knock against the business.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
5 · Moderate
Beta 0.40 and staple demand cut both ways with 3.9× TTM net-debt/EBITDA, a ~96% dividend payout, and a cocoa-driven earnings shock. Defensive but not pristine.
Mature snacking staple; low-single-digit growth with no acceleration and a $78B cap against a saturated TAM. No path to a multibagger.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
Case
Key assumptions
Fair value
Bull
Cocoa normalizes, pricing sticks without volume loss; margin recovers. FY27E EPS beats to ~$3.60 (vs $3.36 cons); multiple re-rates to ~21× on restored quality.
~$76 (+25%)
Base(our anchor)
Estimates roughly hit — FY27E EPS $3.36; a slow ~3% grower with a stretched payout earns a ~19× multiple.
~$64 (+5%)
Bear
Cocoa stays elevated, price hikes drive down volume/mix, private-label share gains; FY27E EPS misses to ~$3.00; multiple de-rates to ~16×.
~$48 (−21%)
Synthos fair value = the base case, ~$64 (+5%), with the full $48–$76 span as the honest range. This anchor sits just below the Street's $67 median (we are a touch more cautious on the pace of margin recovery) and our bull roughly matches the Street's $73 high. This is a tracked call — the Forecaster Scorecard grades it once it matures. Note the thin upside: at ~$64 base vs a $60.91 price, MDLZ is close to fair value, which is precisely why it is a Watch.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). MDLZ is neither an exponential nor even a fast compounder — it is a mature, slow-growth staple:
Forward growth: revenue CAGR FY25→FY30E ~3.1% ($38.35B → $44.73B est); EPS CAGR ~8.0% ($2.89 → $4.26 est), with most of the EPS growth coming from margin recovery off the cocoa trough and buybacks, not volume.
Acceleration (the 2nd derivative) is roughly flat-to-negative: est revenue growth is ~4% (FY26E) easing toward ~3% by FY30E. There is no inflection — this is a steady-state staple, not an accelerating story. Per our flagship philosophy we pick forward next-exponentials over trailing compounders; MDLZ is neither.
Room to run: the global snacking TAM is large but mature and saturated — Mondelez already sells in nearly every market. At a $78B cap, growth comes from pricing, small M&A, and emerging-market volume, not a new demand curve.
Reinvestment runway: capex is modest (~3.3% of revenue) and most cash returns to shareholders via dividend (~96% payout) and buyback — appropriate for a low-reinvestment staple, but the tell that there is little organic growth to fund.
Exponential Potential: Low (2/10). Own MDLZ, if at all, for defensive ballast and ~3.3% yield — never for growth. A $78B staple growing 3% cannot be a multibagger; that is not a criticism, just an honest classification.
Revenue: FY25 $38.54B, +5.8% (FY24 $36.44B, +1.2% on FY23 $36.02B). Growth is pricing-led; underlying volume has been soft as price hikes bite.
The cocoa shock (the story of 2025): GAAP gross margin fell to 28.8% TTM from ~39% in FY24 as cocoa costs spiked. GAAP EBITDA dropped to $4.65B (FY25) from $8.07B (FY24); net income fell to $2.45B from $4.61B, and EPS to $1.89 from $3.44. (Note: management-adjusted EBITDA — the basis for the ~$6.97B FY25 estimate figure — strips much of this out; the GAAP hit is real but partly non-recurring commodity/mark-to-market noise.)
Quarterly trajectory: Q1'25 $9.31B → Q2 $8.98B → Q3 $9.74B → Q4 $10.50B → Q1'26 $10.08B. Revenue is stable; the swing factor is margin, not sales.
Margins: gross 28.8% TTM (depressed), operating ~9.6% TTM, net 6.6% TTM — all cocoa-compressed and expected to recover as pricing catches up.
Cash flow: operating CF $4.51B, capex −$1.28B, FCF $3.24B FY25 — still robust and covers the dividend (~$2.49B paid) plus buyback (~$2.39B), though combined returns slightly exceeded FCF in FY25.
Balance sheet: total debt $22.4B, net debt $20.28B, net-debt/EBITDA 3.9× on TTM GAAP EBITDA (elevated by the cocoa hit; ~2.9× on ~$7B adjusted EBITDA). Current ratio 0.54 — thin, typical for a staple with fast inventory turns. Investment-grade but not a fortress.
6. Valuation — priced in or room?
MDLZ is not obviously cheap and not obviously expensive — it is roughly fair, leaning full. Trailing metrics are distorted by the cocoa hit (30× trailing EPS looks rich, but that's on trough earnings). On normalized/forward numbers the picture is a fairly-valued staple: forward P/E ~20× (FY26E $3.05) → 18× (FY27E $3.36) → 14× (FY30E $4.26) — reasonable for a defensive name but not a discount given only ~3% revenue growth (PEG is unattractive at ~2.5×). EV/EBITDA is 19× TTM (again trough-inflated) versus a more normal ~13–14× on adjusted EBITDA. Street targets (context): median $67, high $73, low $61 — a tight band implying the Street sees ~10% upside plus the ~3.3% yield. Our ~$64 base FV is slightly below that. The dividend yield (~3.3%) and ~96% payout are the real valuation anchor here: you are largely paid to wait for margin recovery. Not a value buy; a fairly-priced defensive holding.
7. Technicals (from the FMP tech block)
Trend:neutral. $60.91 sits essentially on the 50-DMA ($60.97) and above the 200-DMA ($58.84) — a flat-to-mildly-constructive posture, no clear trend. MACD slightly negative (−0.37).
Location:−13.9% off the 52-week high ($70.75), +18.2% off the 52-week low ($51.51), with a max drawdown of −22.3% from peak — a meaningful de-rate over the past year as the cocoa story played out.
Relative strength (the tell): MDLZ is −11.7% over 12 months while SPY is +20.6% and QQQ is +30.3% — a ~32-point lag versus the Nasdaq-100. Over 3 months it's +6.7% (vs SPY +13.7%, QQQ +22.0%), still lagging. This is a laggard, not a leader.
Read: technicals confirm the fundamental caution — no momentum, a persistent relative-strength deficit versus the index. No technical reason to chase; a base needs to form. This reinforces Watch.
8. Moat & competitive position
Mondelez's moat is brand and distribution scale in snacking: category-leading, decades-old brands (Oreo is the world's best-selling cookie; Cadbury/Milka anchor European chocolate) plus a vast direct-store-delivery and retail network across ~150 countries. That produces pricing power and shelf dominance — but it is a mature, low-growth moat, and the current test is whether pricing can be pushed through without ceding volume to private label during a cost spike. Returns are modest (ROE ~10%, ROIC ~5.6%), reflecting a goodwill-heavy balance sheet (intangibles are 62% of assets from the Kraft-era deals).
Peer set (market cap): Altria $121B, Colgate-Palmolive $76B, Monster Beverage $95B, Coca-Cola Europacific $47B, Diageo $46B, Keurig Dr Pepper $45B, Sysco $41B, Hershey $37B (the closest chocolate comp, also cocoa-exposed), Kroger $36B, Kellanova $29B. Within packaged food/snacking, MDLZ is one of the largest and best-diversified, but the whole cohort shares the same slow-growth, input-cost-sensitive profile.
9. Management, capital allocation & guidance
Capital allocation: shareholder-return-led — FY25 paid ~$2.49B in dividends and repurchased ~$2.39B of stock, together modestly above the $3.24B FCF, funded partly by incremental debt (net debt rose ~$3.3B YoY). The ~96% dividend payout leaves little slack if earnings stay depressed; watch for payout discipline if cocoa persists.
Insider activity: recent Form 4s are routine equity awards — the new CFO (Amit Banati) received option/stock awards on 2026-07-01, and directors received standard grants on 2026-05-20. No open-market cluster selling or buying of note in the sampled window; nothing to read into.
Guidance: Mondelez has no expert-KB coverage, and full earnings-call guidance is not on our FMP plan. Management has publicly framed 2025–26 as a cocoa-cost-recovery period reliant on pricing. Gap flagged: we capture prepared guidance from SEC filings; the analyst Q&A transcript could be added via a free source (earningscall.biz) — see the plan note. Treat any forward figure here as analyst estimate, not company promise.
10. Catalysts & what to watch
Next earnings: 2026-07-28 (Q2'26; Street EPS $0.67, revenue ~$9.2B). The key line: gross margin trajectory and pricing/volume elasticity — is pricing sticking without volume loss?
Cocoa/commodity prices: the single biggest swing factor for the whole thesis. A sustained cocoa decline is the bull trigger; persistence is the bear.
Volume/mix vs private label: evidence that price hikes are (or aren't) driving trade-down.
Emerging-market demand & FX: with ~60%+ of revenue ex-US, currency and EM volume matter more than for US-centric peers.
Dividend/payout: any signal on payout sustainability given the ~96% ratio.
Thesis tripwires (what would change the call): two consecutive quarters of volume declines outpacing price; gross margin failing to recover toward the mid-30s; a dividend-growth pause; or cocoa costs making a new sustained leg higher.
11. Key risks
Commodity inflation (structural): cocoa (and sugar/dairy) costs directly hit the chocolate and biscuit margins; 2025 showed how severe the earnings impact can be.
Pricing/volume elasticity: aggressive price hikes risk driving consumers to cheaper private-label snacks, especially in a value-conscious environment.
Leverage & payout: 3.9× TTM net-debt/EBITDA and a ~96% dividend payout leave limited cushion if the margin recovery slips.
FX / emerging-market exposure: majority-ex-US revenue means currency swings and EM demand softness flow straight to results.
Secular snacking/health shifts: GLP-1-driven appetite suppression and health trends are a slow, real long-tail headwind for indulgent-snack volume — worth monitoring, not yet visible in the numbers.
No expert conviction: unlike our high-breadth names, there is zero independent KB support here — the call rests entirely on fundamentals and quant.
12. Verdict, position sizing & monitoring
Watch. Mondelez is a genuinely durable, defensive snacking franchise with strong brands, ~$3.2B FCF, and a ~3.3% yield — but three things keep it off the buy list today: (1) a cocoa-cost shock that halved GAAP earnings and whose recovery pace is uncertain; (2) a full-ish ~20× forward multiple for only ~3% revenue / ~8% EPS growth; and (3) no expert conviction in the Synthos KB, so there is nothing beyond fundamentals to underwrite a higher-conviction stance. With base-case fair value (~$64) only ~5% above the price, the risk/reward is roughly balanced.
Sizing: if held at all, a defensive-satellite ~1–2% for yield and ballast — not a conviction position. Better entries would come on a cocoa-driven washout toward the low-$50s (our bear zone) or clear evidence of margin recovery.
Monitoring: re-underwrite on the tripwires in §10; formal re-score each earnings print, especially the gross-margin line. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $60.91.
Single biggest risk: cocoa/commodity inflation compressing margin faster than pricing can recover it.
Provenance & disclosures
Traceability: 0 KB claims, breadth 0 — no expert coverage. This note is explicitly fundamentals- and quant-driven; no conviction is borrowed or fabricated (claim-ID reconciliation makes fabrication structurally impossible, and there are simply no claims to cite).
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates.
Non-recurring note: FY25 GAAP margin/EBITDA/EPS are depressed by a cocoa-cost shock; adjusted figures (and forward estimates) reflect an expected partial recovery — both are shown and labeled.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").